Supreme Court Hears Arguments on Fosamax, MedShadow Foundation Contributes Amicus Brief

The pharmaceutical company Merck is accused of withholding notification of a serious adverse side effect of Fosamax (and all bisphosphonates), meds used for osteoporosis, from doctors and the public. On Monday the Supreme Court heard arguments from Merck and class action attorneys (the original lead plaintiff is Doris Albrecht) to determine whether Merck took all the proper steps to warn doctors about the side effect — severe femur fractures that usually require surgery to repair.

MedShadow Foundation and three past FDA executives filed an amicus brief (“friend of the court”) to support Albrecht. Suzanne Robotti, founder of MedShadow, was at the hearing and told ABC News that if Merck prevails, “It would be a disaster for patient rights, for patient protection.”


Sarah Rosenthal

Sarah Rosenthal

Sarah Rosenthal is an intern at MedShadow. She is majoring in Biology and Society in the College of Agriculture and Life Sciences at Cornell University with a concentration in food, health, and sustainability, and minoring in Viticulture and Enology.


Did you find this article helpful?


Latest News

News Scan: Breast Cancer, THC Overdose, Carpal Tunnel Syndrome, Junk Food

News Scan: Breast Cancer, THC Overdose, Carpal Tunnel Syndrome, Junk Food

Breast cancer tops the list this week with two research studies concluding worse news than expected. For those who continue to claim that no one overdoses on cannabis or THC, see the story below. Never underestimate how much people will underestimate the power of “herbs” to harm. Carpal tunnel brought…

News Scan: Warfarin, A-Fib, Lavender Oil and Dopamine Agonist Medicine

News Scan: Warfarin, A-Fib, Lavender Oil and Dopamine Agonist Medicine

Every so often a lay person like me slaps her forehead and says out loud, “what took so long?” A veggie works better than a medicine, why not use the veggie? Talking to patients in their home leads to better understanding by the patients? Of course. And less intuitive but…